One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Rapid and novel treatments in psychiatry: the future is now
Carolyn I. Rodriguez & Charles F. ZorumskiÂ
doi : 10.1038/s41386-023-01720-2
Volume 49 Issue 1, January 2024
Finding new and better treatments for psychiatric disorders
Steven M. Paul & William Z. PotterÂ
No time to lose: the current state of research in rapid-acting psychotherapeutics
Joshua A. Gordon, Nora D. Volkow & George F. KoobÂ
The Brain & Behavior Research Foundation’s philanthropic support for neuropsychiatric research
Jeffrey Borenstein, Geoffrey A. Simon & Peter J. TarrÂ
Navigating the FDA regulatory landscape
Pamela D. Scott, Anita Bajaj & David P. McMullenÂ
Ketamine in neuropsychiatric disorders: an update
Jenessa N. Johnston, Bashkim Kadriu, Christoph Kraus, Ioline D. Henter & Carlos A. Zarate JrÂ
Ketamine and rapid antidepressant action: new treatments and novel synaptic signaling mechanisms
John H. Krystal, Ege T. Kavalali & Lisa M. MonteggiaÂ
Therapeutic potential of N-methyl-D-aspartate receptor modulators in psychiatry
Jesse E. Hanson, Hongjie Yuan, Riley E. Perszyk, Tue G. Banke, Hao Xing, Ming-Chi Tsai, Frank S. Menniti & Stephen F. TraynelisÂ
Novel neurosteroid therapeutics for post-partum depression: perspectives on clinical trials, program development, active research, and future directions
Riah Patterson, Irina Balan, A. Leslie Morrow & Samantha Meltzer-BrodyÂ
Neurosteroids: mechanistic considerations and clinical prospects
Jamie L. Maguire & Steven MennerickÂ
Modulators of GABAA receptor-mediated inhibition in the treatment of neuropsychiatric disorders: past, present, and future
Scott M. ThompsonÂ
Psychedelic therapies reconsidered: compounds, clinical indications, and cautious optimism
Jennifer M. Mitchell & Brian T. AndersonÂ
Therapeutic mechanisms of psychedelics and entactogens
Boris D. Heifets & David E. OlsonÂ
Psychedelics: preclinical insights provide directions for future research
Ryan H. Gumpper & Bryan L. RothÂ
Accelerated TMS - moving quickly into the future of depression treatment
Sanne J. H. van Rooij, Amanda R. Arulpragasam, William M. McDonald & Noah S. PhilipÂ
Closing the loop in psychiatric deep brain stimulation: physiology, psychometrics, and plasticity
Alik S. WidgeÂÂ
How electroconvulsive therapy works in the treatment of depression: is it the seizure, the electricity, or both?
Zhi-De Deng, Pei L. Robins, William Regenold, Paul Rohde, Moritz Dannhauer & Sarah H. LisanbyÂ
Closed-loop neurostimulation for the treatment of psychiatric disorders
Kristin K. Sellers, Joshua L. Cohen, Ankit N. Khambhati, Joline M. Fan, A. Moses Lee, Edward F. Chang & Andrew D. KrystalÂ
The future of brain circuit-targeted therapeutics
Shan H. Siddiqi, Sanaz Khosravani, John D. Rolston & Michael D. FoxÂ
The why, when, where, how, and so what of so-called rapidly acting antidepressants
Alan F. Schatzberg & Sanjay J. MathewÂ
How should we design future mechanistic and/or efficacy clinical trials?
Maurizio FavaÂ
Digital and precision clinical trials: innovations for testing mental health medications, devices, and psychosocial treatments
Eric Lenze, John Torous & Patricia AreanÂ
Advancing preclinical chronic stress models to promote therapeutic discovery for human stress disorders
Trevonn M. Gyles, Eric J. Nestler & Eric M. PariseÂ
The role of neurotrophic factors in novel, rapid psychiatric treatments
Jihye Kim, Michelle J. He, Alina K. Widmann & Francis S. LeeÂ
Antidepressants enter cells, organelles, and membranes
Zack Blumenfeld, Kallol Bera, Eero Castrén & Henry A. LesterÂ
Novel mechanism-based treatments for pediatric anxiety and depressive disorders
Chad M. Sylvester, Joan L. Luby & Daniel S. PineÂ
Are novel treatments for brain disorders hiding in plain sight?
Laramie Duncan & Karl DeisserothÂ
Pharmacogenomic testing for antidepressant treatment selection: lessons learned and roadmap forward
Mark A. Frye & Charles B. NemeroffÂ
Electronic health records and stratified psychiatry: bridge to precision treatment?
Adrienne Grzenda & Alik S. WidgeÂ
Ethical considerations in rapid and novel treatments in psychiatry
Tobias Haeusermann & Winston ChiongÂ
Ensuring psychedelic treatments and research do not leave anyone behind
Melissa A. SimonÂ
Correction: Ethical considerations in rapid and novel treatments in psychiatry
Tobias Haeusermann & Winston ChiongÂ
Correction: Accelerated TMS - moving quickly into the future of depression treatment
Sanne J. H. van Rooij, Amanda R. Arulpragasam, William M. McDonald & Noah S. PhilipÂ
Correction: Digital and precision clinical trials: innovations for testing mental health medications, devices, and psychosocial treatments
Eric Lenze, John Torous & Patricia AreanÂ
Cell type specific focused ultrasound neuromodulation in preclinical models of sleep and psychiatric disorders
Keith R. Murphy & Luis de LeceaÂ
Disassociating drug active ingredients from inactive: ketamine-like synaptic effects of a ketamine excipient
Kyle A. Brown & Todd D. GouldÂ
Unraveling the cell-type-specific molecular pathways of PTSD: integrating GWAS with brain genomic profiling and in vitro modeling
Artemis Iatrou & Nikolaos P. DaskalakisÂ
Potential applications of temporal interference deep brain stimulation for the treatment of transdiagnostic conditions in psychiatry
Negar Fani & Michael T. TreadwayÂ
Kynurenic acid: translational perspectives of a therapeutically targetable gliotransmitter
Ana Pocivavsek & Sophie ErhardtÂ
Neurobiology and treatment advances for prolonged grief disorder
Zoe R. Donaldson & M. Katherine ShearÂ
A novel rat model of potentiated incubation of opioid craving after abstinence induced by adverse consequences of drug seeking
Ida Fredriksson & Yavin ShahamÂ
Herpesviruses and neuropsychiatric disorders: overlooked adversaries or innocent bystanders?
Haixia Zheng & Jonathan SavitzÂ
Exploring the role of mu opioid receptors in the therapeutic potential and abuse liability of (S)-ketamine
Marjorie R. Levinstein & Michael MichaelidesÂ
Repurposing anti-inflammatory medications for alcohol and substance use disorders
Angela R. Ozburn & Sade M. SpencerÂ
Integrating public health and translational basic science to address challenges of xylazine adulteration of fentanyl
Cassandra D. Gipson & Justin C. StricklandÂ
A path to novel, effective treatments for schizophrenia
Thomas W. Weickert & Cynthia Shannon WeickertÂ
Moving beyond descriptive nosology: an argument for negative valence systems disorder
Elizabeth K. Lucas & Robert E. McCullumsmithÂ
From high-throughput transcriptome characterization of individual synaptosomes to constructing the whole-brain connectome
Muchun Niu & Chenghang ZongÂ
Swell1 channel-mediated tonic GABA release from astrocytes modulates cocaine reward
Junhua Yang & Zhaozhu QiuÂ
The orexin neurotransmitter system as a target for medication development for opioid use disorder
A. S. Huhn & K. E. DunnÂ
A unique role for cAMP signaling in microglia during opioid tolerance and withdrawal
Kevin R. Coffey & John F. NeumaierÂ
Epigenetic alterations identify a confluence of genetic vulnerabilities tied to opioid overdose
An T. Hoang & Olivia CorradinÂ
Leveraging AI to predict substance use disorder treatment outcomes
Salvatore Giorgi & Brenda CurtisÂ
The biological embedding of structural inequities: new insight from neuroscience
E. Kate Webb & Nathaniel G. HarnettÂ
Potentiation of AMPA receptors for rapid therapeutic gain in psychiatry has reached a new level of excitement
Jeffrey M. Witkin & Arnold LippaÂ
Central amygdala CRF1 cells control nociception and anxiety-like behavior
Marcus M. Weera & Nicholas W. GilpinÂ
Gene–brain–behavior mechanisms underlying autism spectrum disorder: implications for precision psychiatry
Amanda M. Buch & Conor ListonÂ
Microbes and mental health: translating preclinical findings to the clinic
Cherise R. Chin Fatt & Madhukar H. TrivediÂ
Towards personalized medicine: subtyping using functional profiles
Gunner Drossel & Anna ZilverstandÂ
Postmortem-derived iPSC models in substance use disorders research
Emily Frances Mendez & Consuelo Walss-BassÂ
Transcranial focused ultrasound (tFUS): a promising noninvasive deep brain stimulation approach for pain
Bashar W. Badran & Xiaolong PengÂ
